Shree Ganesh Remedies Ltd (SGRL) is currently trading at 424.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Shree Ganesh Remedies Limited specializes in manufacturing pharmaceutical intermediates and fine chemicals, emphasizing complex chemistry and niche specialty chemicals. With over 20 years of experience, they have a robust export portfolio serving over 20 countries, including the EU and US. The company has embarked on significant capacity expansions, commissioning a pilot plant and advancing new production facilities, reflecting strong infrastructural growth. This expansion supports increased production capacity and positions the company favorably for future demand. Despite a YoY revenue decline, primarily due to softened demand in Europe, Shree Ganesh Remedies shows resilience through improved sequential growth, crediting process optimization and strategic contract repricing. This suggests a resilient financial performance amidst challenging market conditions. SGRL's management highlights the strategic shift towards complex and patented specialty chemicals. This transition reflects a strategic move from generic pharmaceutical intermediates to innovative, high-margin products with significant market potential. Ongoing R&D investments and technological advancements are core to SGRL's strategy, fostering innovation and enhancing its product portfolio. The company's focus on proprietary chemistry and backward integration creates a competitive advantage in custom synthesis and specialty chemicals.

Over the past 52 weeks, Shree Ganesh Remedies Ltd has traded between a low of ₹399.95 and a high of ₹950.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Shree Ganesh Remedies Ltd has a market capitalization of approximately 540.66. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Shree Ganesh Remedies Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 26.49 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of Shree Ganesh Remedies Ltd (SGRL) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 540.66 Cr, Shree Ganesh Remedies Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Shree Ganesh Remedies Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Shree Ganesh Remedies Ltd is 26.49. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Shree Ganesh Remedies Ltd currently does not pay dividends. Companies that do not pay dividends often reinvest profits to support business growth or strengthen operations.

Key risks associated with Shree Ganesh Remedies Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.